Long-Term Response to Ovariectomy in 35 Premenopausal Patients with Advanced Breast Cancer, Treated in Coherence with Hormonal Tests

1983 ◽  
Vol 69 (4) ◽  
pp. 343-347 ◽  
Author(s):  
Ferdinando Preda ◽  
Sara Oriana ◽  
Giovanni Di Fronzo ◽  
Giorgio Secreto ◽  
Aldo Severini ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Hormone Therapy ◽  
Locally Advanced Breast Cancer ◽  
Locally Advanced ◽  
Advanced Breast ◽  
Premenopausal Patients ◽  
Term Response ◽  
Actuarial Method

Thirty-five premenopausal patients with metastasized or locally advanced breast cancer underwent ovariectomy. At relapse, after surgery, they were treated with hormone therapy or chemotherapy, according to hormonal tests carried out before the castration. Five-year survival, computed with the actuarial method, confirmed the better prognosis of the hormone-dependent patients and also an improved prognosis in the patients treated with hormone therapy after ovariectomy. Furthermore, chemotherapy proved more efficacious: an increased survival was observed in the non-hormone-dependent patients.

Long-term Survival after Cerebellar Metastasis Resection from Her2 3+ Locally Advanced Breast Cancer

2015 ◽  
Vol 11 (1) ◽  
pp. 36
Author(s):  
Zorica I Tomasevic ◽  
Zoran M Tomasevic ◽  
Zeljko Kovac ◽  
Zorka Milovanovic ◽  
Dana Grujicic ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Locally Advanced Breast Cancer ◽  
Locally Advanced ◽  
Advanced Breast ◽  
Disease Course ◽  
Term Survival ◽  
Cerebellar Metastasis ◽  
Distant Metastatic Site

We present a patient who first developed a distant metastatic site in the cerebellum during treatment for Her2 3+ locally advanced breast cancer (LABC). LABC was in complete remission at that time and isolated cerebellar metastasis was resected. The patient is still alive more than 135 months after LABC diagnosis, and more than 99 months after neurosurgery, and is still receiving trastuzumab without further progression or any toxicity. To the best of our knowledge, this is first report of such exceptional disease course for a patient with a predicted grave prognosis according to all prognostic parameters.

scholarly journals Long-Term Survival of Women with Locally Advanced Breast Cancer with ≥10 Involved Lymph Nodes at Diagnosis

2014 ◽  
Vol 15 (8) ◽  
pp. 3435-3441 ◽  
Author(s):  
Simon Blechman Zeichner ◽  
Ludimila Cavalcante ◽  
Gabriel Pius Suciu ◽  
Ana Lourdes Ruiz ◽  
Alicia Hirzel ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Nodes ◽  
Advanced Breast Cancer ◽  
Locally Advanced Breast Cancer ◽  
Locally Advanced ◽  
Advanced Breast ◽  
Term Survival ◽  
Long Term Survival

A phase II trial of a neoadjuvant platinum-containing regimen for locally advanced breast cancer: Pathologic response, long-term follow-up, and correlation with biomarkers

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e11510-e11510
Author(s):  
T. N. Shenkier ◽  
M. Hayes ◽  
K. A. Gelmon ◽  
S. Chia ◽  
C. Bajdik ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Advanced Breast Cancer ◽  
Locally Advanced Breast Cancer ◽  
Locally Advanced ◽  
Advanced Breast ◽  
Double Negative ◽  
Negative Group

e11510 Background: To determine the response, tolerability, and long-term outcome of a neoadjuvant platinum-containing regimen for locally advanced breast cancer (LABC). To search for correlation between pathologic complete response (pCR) and predefined biomarkers in this cohort. Patients and Methods: Patients with LABC received eight cycles of either sequence A or B. Sequence A was doxorubicin 60 mg/m2 and paclitaxel 175 mg/m2 (AT) q3w X 4 followed by cisplatin (C) 60 mg/m2 and paclitaxel 90 mg/m2 (CT) q2w X 4. Sequence B was CT x 4 followed by AT x 4. In addition to estrogen receptor and HER2, immunohistochemistry (IHC) for MDR-1, MRP-1, topoisomerase IIα(topoIIα) and p53 was performed. Results: 88 patients were evaluable for response and toxicity. Median follow-up was 97 months. The overall pCR rate was 21.5%. For subgroups ER+/HER2-, HER2 +, and double negative (ER-/ HER2-) disease the pCR was 5.9%,23.3% and 35% respectively, p=0.006. Five year(y) overall survival for the entire cohort was 71.1%. Five y overall survival was 88.1% (CI 77.1%, 99.1%) for the ER positive HER2 negative group compared to 68.5% (CI 51.3%, 85.7%) and 49.5 (CI 27.4%, 71.6%) in the HER2 positive and “double negative” group respectively (p=0.0077). Over-expression of topo IIα was correlated with pCR (p<0.001). There were no toxic deaths. Conclusions: A platinum-containing neoadjuvant regimen was well tolerated and achieved a pCR rate which compares favorably to other recent studies of multi-agent chemotherapy. Further studies tailored for specific breast cancer subtypes are required. No significant financial relationships to disclose.

Locally advanced breast cancer treated with neutron beams: Long-term follow-up in 28 patients

1990 ◽  
Vol 18 (4) ◽  
pp. 825-831 ◽  
Author(s):  
Joshua Halpern ◽  
Moshe H. Maor ◽  
David H. Hussey ◽  
Gregory C. Henkelmann ◽  
Vincent Sampiere ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Locally Advanced Breast Cancer ◽  
Locally Advanced ◽  
Advanced Breast ◽  
Neutron Beams ◽  
Long Term Follow Up

Long-term cosmetic outcome after preoperative radio-/chemotherapy in locally advanced breast cancer patients

2019 ◽  
Vol 195 (7) ◽  
pp. 615-628 ◽  
Author(s):  
Christiane Matuschek ◽  
Carolin Nestle-Kraemling ◽  
Jan Haussmann ◽  
Edwin Bölke ◽  
Sylvia Wollandt ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Cancer Patients ◽  
Locally Advanced Breast Cancer ◽  
Locally Advanced ◽  
Cosmetic Outcome ◽  
Advanced Breast ◽  
Breast Cancer Patients ◽  
Radio Chemotherapy

Multimodality Treatment of Locally-Advanced Breast Cancer Using 6.3 MeV Fast Neutrons and Quality of Life in Patients in Long-Term Follow-Up

2015 ◽  
Vol 1084 ◽  
pp. 406-408
Author(s):  
Zhanna Startseva ◽  
Ludmila Musabaeva ◽  
Valerij Lisin
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Locally Advanced Breast Cancer ◽  
Locally Advanced ◽  
Multimodality Treatment ◽  
Advanced Breast ◽  
Long Term Results ◽  
Fast Neutrons ◽  
Combined Modality Treatment

The purpose of the study is to present the 10-year results of the combined modality treatment with the use of neutron-photon therapy for patients with T2-4N0-2M0 locally advanced breast cancer (LABC). The study involved 246 LABC patients (T2-4N0-2M0). Analysis of long-term results of multimodality treatment of patients with primary LABC has shown that preoperative neutron therapy is the most effective in the presence of multicentric tumors, radioresistance to neoadjuvant chemotherapy and other adverse prognostic factors.

scholarly journals VRAM flap for locally advanced breast cancer

Mastology ◽  
2021 ◽  
Vol 31 ◽  
Author(s):  
René Aloisio da Costa Vieira ◽  
Raphael Luiz Haikel ◽  
Luciano Ipólito Branquinho ◽  
Idam de Oliveira-Junior
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Myocutaneous Flap ◽  
Locally Advanced Breast Cancer ◽  
Locally Advanced ◽  
Radical Mastectomy ◽  
Advanced Breast ◽  
Extensive Resection ◽  
Vram Flap

The authors presented a case of a patient with locally advanced breast cancer, with mammary and axillary localization, initially considered non-resectable, with good response after neoadjuvant chemotherapy. Due to the location of the lesion and the need for extensive resection, radical mastectomy was performed, associated with reconstruction with myocutaneous flap of the vertical rectus abdominis muscle. Different therapeutic options, the reasons that determine this choice, and local long-term control were discussed.

Sign in / Sign up

Export Citation Format

Share Document